Anebulo Pharmaceuticals (FRA:214) Total Liabilities: €1.27 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:214 Anebulo Pharmaceuticals Inc FRA:214
35 GF Score
Price €0.75
! 1 Warning Sign
View Full Analysis

What is Anebulo Pharmaceuticals Total Liabilities?

Anebulo Pharmaceuticals FRA:214 35 Total Liabilities is €1.27 Mil as of Dec. 2025. GuruFocus rates FRA:214 with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Anebulo Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 was €1.27 Mil.

Anebulo Pharmaceuticals's quarterly Total Liabilities increased from Jun. 2025 (€0.42 Mil) to Sep. 2025 (€0.82 Mil) and increased from Sep. 2025 (€0.82 Mil) to Dec. 2025 (€1.27 Mil).

Anebulo Pharmaceuticals's annual Total Liabilities declined from Jun. 2023 (€0.99 Mil) to Jun. 2024 (€0.24 Mil) but then increased from Jun. 2024 (€0.24 Mil) to Jun. 2025 (€0.42 Mil).

Anebulo Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Anebulo Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anebulo Pharmaceuticals Total Liabilities Chart

Anebulo Pharmaceuticals Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Liabilities
Get a 7-Day Free Trial 0.20 0.49 0.99 0.24 0.42

Anebulo Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.84 0.51 0.42 0.82 1.27
FRA:214
35GF Score
Anebulo Pharmaceuticals Inc FRA:214
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anebulo Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Anebulo Pharmaceuticals's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.423+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.42

Total Liabilities=Total Assets (A: Jun. 2025 )-Total Equity (A: Jun. 2025 )
=10.531-10.107
=0.42

Anebulo Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.269+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.27

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=8.046-6.777
=1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €1.27 Mil mean?
Anebulo Pharmaceuticals (FRA:214) has a Total Liabilities of €1.27 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Anebulo Pharmaceuticals and its competitors.
Is Anebulo Pharmaceuticals' Total Liabilities too high?
Anebulo Pharmaceuticals' current Total Liabilities is €1.27 Mil. Overall, Anebulo Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Anebulo Pharmaceuticals' Total Liabilities compare to PHIO and COCP?
Anebulo Pharmaceuticals' Total Liabilities of €1.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Anebulo Pharmaceuticals and its competitors. Anebulo Pharmaceuticals's current Total Liabilities is €1.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anebulo Pharmaceuticals stock overvalued right now?
Anebulo Pharmaceuticals (FRA:214) has a current Total Liabilities of €1.27 Mil. The current Total Liabilities is €1.27 Mil. Anebulo Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Anebulo Pharmaceuticals (FRA:214), the current Total Liabilities is €1.27 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anebulo Pharmaceuticals Business Description

Other Exchanges ANEB:USA
Address 1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
35GF Score

Get the complete analysis for FRA:214

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.75
Price